Please try another search
PharmAust Limited develops targeted cancer therapeutics for humans and animals in Switzerland, Australia, Sweden, the United States, and internationally. The company develops drug discovery intellectual property for the treatment of various cancers, neurological diseases, and viral infections. Its lead candidate is Monepantel (MPL), a small molecule drug which is in Phase II clinical trials for the treatment of cancer. The company also provides products and services in synthetic and medicinal chemistry to the drug discovery and pharmaceutical industries worldwide. It serves drug discovery and pharmaceutical industries. PharmAust Limited was incorporated in 2000 and is based in Bentley, Australia.
Name | Age | Since | Title |
---|---|---|---|
John Horton | - | - | Director of Epichem Pty Ltd |
Rebecca McCrackan | - | 2016 | Director of Epichem Pty Ltd |
Robert Charles Bishop | - | 2013 | Executive Director |
Angela Frimberger | - | 2017 | Veterinary Clinical Advisory Board Chair |
Christian Schirvel | - | 2017 | Veterinary Clinical Advisory Board Member |
Barbara Kitchell | - | 2017 | Veterinary Advisory Board Member |
Marcus Paul Hughes | - | 2024 | Director |
Sergio Duchini | - | 2024 | Non-Executive Chairman |
Michael Thurn | - | 2024 | MD, CEO & Director |
Kathryn MacFarlane | 58 | 2024 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review